CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination

Cancer Research

Volumn 76, Issue 10, 2016, Pages 2921-2931

  Ahrends, Tomasz ^a   Babała, Nikolina ^a   Xiao, Yanling ^a   Yagita, Hideo ^b   Van Eenennaam, Hans ^c   Borst, Jannie ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Aduro BioTech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD70 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; EPITOPE; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN E7; CANCER VACCINE; CTLA4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; INTRAEPIDERMAL DRUG ADMINISTRATION; LONG TERM SURVIVAL; MALE; MEMORY T LYMPHOCYTE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TUMOR REGRESSION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; C57BL MOUSE; CELL PROLIFERATION; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TUMOR CELL CULTURE; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD27; APOPTOSIS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CTLA-4 ANTIGEN; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED; VACCINATION;

EID: 84965147409     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3130     Document Type: Article

References (48)

1. Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest 2015;125:3401-12.
2. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011;131:509-17.
3. Steinman RM.Dendritic cells in vivo: A key target for a new vaccine science. Immunity 2008;29:319-24.
4. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008;224:166-82.
5. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: A molecular basis for the cellextrinsic function of CTLA-4. Science 2011;332:600-3.
6. Schenten D, Medzhitov R. The control of adaptive immune responses by the innate immune system. Adv Immunol 2011;109:87-124.
7. Bevan MJ.Helping the CD8() T-cell response. Nat Rev Immunol 2004;4: 595-602.
8. Arens R, Schoenberger S. Plasticity in programming of effector andmemory CD8 formation. Immunol Rev 2010;235:190-205.
9. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 1996;93:7855-60.
10. Kenter G, Welters M, Valentijn R, LowikM, Berends-vanderMeer D, Vloon A, et al. Vaccination against HPV-16 oncoproteins for vulvar intra-epithelial neoplasia. N Engl J Med 2009;361:1838-47.
11. Melief CJM, Van Der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008;8: 351-360.
12. Schoenberger SP, Toes R, van der Voort E. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-3.
13. Diehl L, Den Boer A, Schoenberger SP, Voort EIH, Schumacher TNM, Melief CJM, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999;5:774-9.
14. Smith CM, Wilson SN, Waithman J, Villadangos JA, Carbone FR, Heath WR, et al. Cognate CD4 T cell licensing of dendritic cells in CD8 T cell immunity. Nat Immunol 2004;11:1143-8.
15. Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med 2003;198:1369-80.
16. Watts TH.TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68.
17. Schaer DA, Hirschhorn-Cymerman D, Wolchok JD. Targeting tumornecrosis factor receptor pathways for tumor immunotherapyy. J Immunother Cancer 2014;2:7.
18. Callahan MK, Postow MA, Wolchok JD CTLA-4 and PD-1 pathway blockade: Combinations in the clinic. Front Oncol 2014;4:385.
19. Chen DS, Mellman I. Oncologymeets immunology: The cancer-immunity cycle. Immunity 2013;39:1-10.
20. Bins AD, Jorritsma A, Wolkers MC, Hung C, Wu T, Schumacher TNM, et al. A rapid and potentDNAvaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005;11:899-904.
21. Verstrepen BE, Bins AD, Rollier CS, Mooij P, Koopman G, Sheppard NC, et al. Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine 2008;26:3346-51.
22. Oosterhuis K, Aleyd E, Vrijland K, Schumacher TN, Haanen JB.Rational design of DNA vaccines for the induction of Human Papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses. Hum Gene Ther 2012;23:1301-12.
23. Bins AD, Van Rheenen J, Jalink K, Halstead R, DivechaN, Spencer DM, et al. Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnol 2007;7:2.
24. Oshima H, Nakano H, Nohara C, Kobata T, Nakajima A, Jenkins N, et al. Characterization of murine CD70 by molecular cloning and mAb. Int Immunol 1998;10:517-26.
25. Sakanishi T, Yagita H. Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice. Biochem Biophys Res Commun 2010;393:829-35.
26. Lin KY, Guarinieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
27. Rice J, Elliott T, Buchan S, Stevenson FK. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: Implications for cancer vaccines. J Immunol 2001;167:1558-65.
28. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modificationofhigh affinityDR-blocking peptides. Immunity 1994;1:751-61.
29. Barber DL, Wherry EJ, Ahmed R. Cutting edge: Rapid in vivo killing by memory CD8 T cells. J Immunol 2003;171:27-31.
30. Castellino F, Germain RN. Cooperation between CD4 and CD8 T cells: When, where, and how. Anv Immunol 2006;24:519-40.
31. Eickhoff S, Brewitz A, Gerner MY, Klauschen F, Komander K, Hemmi H, et al. Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions. Cell 2015;162:1322-37.
32. Nolte MA, VanOlffen RW, Van Gisbergen KPJM, Van Lier RAW. Timing and tuning of CD27-CD70 interactions: The impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 2009;229:216-31.
33. Peperzak V, Veraar EAM, Keller AM, Xiao Y, Borst J. The Pim kinase pathway contributes to survival signaling in primed CD8 T cells upon CD27 costimulation. J Immunol 2010;185:6670-8.
34. van Gisbergen KPJM, Klarenbeek PL, Kragten NAM, Unger PA, Nieuwenhuis MBB, Wensveen FM, et al. The costimulatory molecule CD27 maintains clonally diverse CD8() T cell responses of low antigen affinity to protect against viral variants. Immunity 2011;35:97-108.
35. Sanchez PJ, McWilliams JA, Haluszczak C, Yagita H, Kedl RM. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J Immunol 2007;178:1564-72.
36. Bullock TN, Yagita H. Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8 T cell responses in the absence of CD4 T cells. J Immunol 2005;174:710-7.
37. Peperzak V, Veraar EAM, Xiao Y, Babala N, Thiadens K, Brugmans M, et al. CD8 T cells produce the chemokine CXCL10 in response to CD27/CD70 costimulation to promote generation of the CD8 effector T cell pool. J Immunol 2013;191:3025-36.
38. Feau S, Garcia Z, Arens R, Yagita H, Borst J, Schoenberger SP. The CD4 Tcell help signal is transmitted from APC to CD8 T-cells via CD27-CD70 interactions. Nat Comm 2012;3:948.
39. Pen JJ, De Keersmaecker B, Maenhout SK, Van Nuffel AMT, Heirman C, Corthals J, et al. Modulation of regulatory T cell function by monocytederived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70. J Immunol 2013;191:1976-83.
40. Xiao Y, Peperzak V, Keller AM, Borst J. CD27 instructs CD4 T cells to provide help for the memory CD8 T cell response after protein immunization. J Immunol 2008;181:1071-82.
41. van der Burg SH, Arens R, Melief CJM. Immunotherapy for persistent viral infections and associated disease. Trends Immunol 2011;32:97-103.
42. Bos R, Sherman LA. CD4 T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8 T lymphocytes. Cancer Res 2010;70:8368-77.
43. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
44. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275-80.
45. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73:3591-603.
46. Arens R, Schepers K, Nolte MA, van Oosterwijk MF, van Lier RA, Schumacher TN, et al. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8 T cell formation. J Exp Med 2004;199:1595-605.
47. Keller AM, Schildknecht A, Xiao Y, vandenBroek M, Borst J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8 T cell tolerance and permits effective immunity. Immunity 2008;29:934-46.
48. HeL-Z, ProstakN, Thomas LJ, Vitale L, Weidlick J, CrockerA, et al.Agonist antihuman CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol 2013;191:4174-83.